Navigation Links
Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic
Date:9/25/2007

PINE BROOK, N.J., Sept. 25 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced it has been awarded a contract for $12 million for advanced development of Anthim(TM), the company's late-stage anthrax therapeutic. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health and the Biomedical Advanced Research and Development Authority, Department of Health and Human Services, under Contract No. HHSN272200700035C. To date, Elusys has received more than $32 million from NIAID/BARDA and the Department of Defense in support of Anthim and the company's Heteropolymer Antibody(TM) technology.

Elizabeth Posillico, Ph.D., President and Chief Executive Officer of Elusys, commented on the award, "Elusys is encouraged by the continued support from the U.S. Government and we look forward to extending our collaboration with NIAID/BARDA. We are confident that Elusys has developed a highly effective and valuable anthrax therapeutic for procurement under Project BioShield for addition to the U.S. Government's Strategic National Stockpile."

Dr. Posillico continued, "Inhalation of anthrax spores rapidly leads to death if patients are not treated immediately with specific antibiotics. Typically, victims of inhalation anthrax experience only vague symptoms until it is too late, when they are in toxemia, leaving antibiotics largely ineffective. Anthrax vaccines are also ineffective unless victims are immunized well in advance of exposure. Anthim represents a 'just in time anthrax therapeutic,' that in relevant models has demonstrated complete protection against an anthrax spore challenge with a single prophylactic dose, and has shown significant protection when administered up to two days after a lethal spore challenge,
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
5. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
6. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
7. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
8. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
9. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
10. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
11. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Una presentazione speciale durante la settimana ... esperti di MERG valutare i successi ottenuti ... di svariate popolazioni di pazienti affetti dalla patologia. ... Ronnie Fass , MD della Case Western Reserve ... clinici relativi alla terapia Stretta. Un panel di esperti ...
(Date:5/27/2015)... Biosensors International Group, Ltd. ("Biosensors " or the "Company", ... manufacturer and marketer of innovative medical devices, today announced ... and fiscal full year ended 31 March 2015 ("FY15"). ... , Q4 FY15: , Total revenue of US$75.9 ... Year 2014 ("Q4 FY14") due to licensing revenue reduction ...
(Date:5/27/2015)... , May 27, 2015  PDL BioPharma, Inc. (PDL) ... P. McLaughlin , the company,s president and chief executive ... Conference next week in New York City.  The presentation, ... 3, 2015 at 11:30 a.m. EDT. To ... presentation, go to the Company,s website at http://www.pdl.com ...
Breaking Medicine Technology:Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 2Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 3Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 4Biosensors Reports Financial Results for Fiscal Year 2015 2Biosensors Reports Financial Results for Fiscal Year 2015 3Biosensors Reports Financial Results for Fiscal Year 2015 4Biosensors Reports Financial Results for Fiscal Year 2015 5Biosensors Reports Financial Results for Fiscal Year 2015 6Biosensors Reports Financial Results for Fiscal Year 2015 7PDL BioPharma to Present at Jefferies 2015 Global Healthcare Conference 2
... Encouraging 12-Month Outcomes from, Single- Center Study Involving ... 14 OrbusNeich today announced that an,interim analysis ... show good safety and efficacy in the real-world ... Presented by Professor Robbert de Winter, M.D., Ph.D., ...
... study Study needed ... Oct. 13 Advanced Circulatory Systems, Inc.,( http://www.advancedcirculatory.com ) ... in funding from the National Institutes of,Health (NIH) to ... on,those who experience cardiac arrest outside a hospital. Whatcom ...
Cached Medicine Technology:Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2
(Date:5/27/2015)... The news is full of companies getting ... documentation or appropriate training: an automobile manufacturer, a store ... company in Texas and the list goes on. The ... due to improper training and documentation (Osha.gov). eLeaP ... the new Supervisor feature which provides a powerful tool ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Danish scientists ... line” biomarkers that have the potential to help in ... to read the full story that has just ... University in Aalborg, Denmark say new biomarkers found in ... outlook for patients with malignant mesothelioma . ...
(Date:5/27/2015)... The Society for Women's Health Research ... research on sex differences in health and disease, today ... advocates, organizations, and celebrities in bringing awareness to the ... campaign features a short film that shares the stories ... as a result of their abuse, as well as ...
(Date:5/27/2015)... May 27, 2015 National ... partner, award winning web development and interactive ... announce the launch of its newly redesigned, ... , National Healthcare Providers, is a physician ... in the areas of Radiology, Anesthesiology, Emergency ...
(Date:5/27/2015)... silver spring, MD (PRWEB) May 27, 2015 ... Company in USA, helped its client to launch an ... Payment app allows merchants to accept credit, debit and ... be downloaded from Google Play at: https://play.google.com/store/apps/details?id=com.simpalm.paymentgateway . ... Jan 2013 and has been recently updated by SIMpalm. ...
Breaking Medicine News(10 mins):Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 3Health News:New Report Highlights Current and Emerging Biomarkers for Mesothelioma, According to Surviving Mesothelioma 2Health News:The Society for Women’s Health Research Announces “Beyond the Bruises” Campaign Highlighting the Effects of Domestic Violence on Chronic Disease 2Health News:The Society for Women’s Health Research Announces “Beyond the Bruises” Campaign Highlighting the Effects of Domestic Violence on Chronic Disease 3Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 2Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 3Health News:Forte Payment System Launches Android Version of Payment App 2
... CARLSBAD, Calif., Oct. 2 Isis,Pharmaceuticals, Inc. (Nasdaq: ... received,clearance under the Hart-Scott-Rodino Antitrust Improvements Act for ... company, which,was announced on September 13, 2007. ... to Ortho-McNeil,worldwide development and commercialization rights to two ...
... for a loved one with dementia, TUCSON, Ariz., ... a new book that aims to ease the challenges ... and,Families are Still Asking WHY?, author Jim Greenwood, whose ... and useful,advice on how to best care for a ...
... Recruitment Efforts for Pulmonary Study, SOLANA ... Solutions, LLC, a firm specializing in patient ... its team of Regional Recruitment,Specialists(TM) in support ... of,Chronic Obstructive Pulmonary Disease (COPD) for a ...
... for Massachusetts Firms, WASHINGTON, Oct. 1 ... bill with provisions secured by,Senator John Kerry (D-Mass.) ... through 2010 and to increase the transition and,commercialization ... will ensure that the thousands of firms that ...
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) announced ... (FDA) has approved the SymlinPen(TM) 120 and ... acetate) injection. These new pre-filled pen-injector devices,feature ... control. "SymlinPen 120 and SymlinPen 60 ...
... any period of time after leaving the foster care ... than those with stable housing situations, according to a ... & Adolescent Medicine, one of the JAMA/Archives journals. Youth ... after leaving the foster care system appear to have ...
Cached Medicine News:Health News:Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc. 2Health News:Alzheimer's Caregivers Get Sage Advice 2Health News:RESolutions Rapid Enrollment Solutions, LLC Mobilizes Team of Regional Recruitment Specialists(TM) 2Health News:Kerry Extends, Improves Small Business Innovation Program 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 3Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 4Health News:Poor health care access common among youth leaving foster system 2Health News:Poor health care access common among youth leaving foster system 3
... Sysmex UF-50 is designed to bring efficiency ... It combines the superior technology of ... sample analysis. Continuous sampling or batch ... autosamplers, streamlining sample processing in high volume ...
... The iQ200 System incorporates the ... and the AUTION MAX™ AX-4280 Automated ... a fully integrated chemical and microscopic ... (APR™), a well trained neural network, ...
... The Sysmex UF-100 is designed to bring ... analysis. It combines the superior technology ... urine sample analysis. Continuous sampling or ... rack-based autosamplers, streamlining sample processing in high ...
... easy to use Ambulatory Urodynamic recorder which ... practising urologists as an invaluable aid in ... The system offers the possibility to measure ... natural bladder filling, extented over a longer ...
Medicine Products: